Rajaratnam Misses Court After Surgery, No Jury Deliberations Today

May 3 2011 | 4:08am ET

Medical matters dominated the sixth day of deliberations at the Raj Rajaratnam insider-trading trial, which ended as the five previous days ended: without a verdict.

Rajaratnam himself wasn't in the courtroom: The Galleon Group chief was excused by U.S. District Judge Richard Holwell, having had emergency surgery to treat a bacterial infection of his foot on Sunday.

"It is hoped that he will be recovered sufficiently to return to the courthouse this week," Rajaratnam's lawyer, John Dowd, said in a statement. "The court has approved this absence."

Holwell echoed that statement before dismissing the jury, telling them that Rajaratnam "couldn't be here and I've excused him for a good reason."

None of them will be there today: A juror's medical procedure has pre-empted the deliberations, which will enter their seventh day tomorrow. The delay came after the jurors sent Holwell a note yesterday—their first communication with the court since Wednesday. The note, dealing with the medical issue, was not released, but Holwell's letter to the jury was.

"No juror should feel any time pressure whatsoever," he wrote. "The jury will have all the time it needs to reach its verdict."

As for Rajaratnam, his spokesman, Jim McCarthy, said he understood that Rajaratnam would not have to be in court tomorrow. He added that he believed a verdict could be handed down whether or not Rajaratnam is present.

If Rajaratnam is convicted, he faces decades in prison.


In Depth

GSAM's Papagiannis: Liquid Alternatives For The Long Run

Apr 21 2017 | 8:44pm ET

Interest in liquid alternatives cooled a bit last year amid a broad shift in investor...

Lifestyle

Aston Martin Returns To Debt Market As DB11 Drives Turnaround

Mar 31 2017 | 5:21pm ET

James Bond’s preferred carmaker is returning to the public debt markets for the...

Guest Contributor

Debunking Conventional Investment Wisdom (Part II)

Apr 17 2017 | 5:56pm ET

The alternative investment industry is currently replete with buzzwords around data...

 

From the current issue of